TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04819841: Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

Sponsor: Kamau Therapeutics · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$931,260

Rescue Site Savings

+$620,840

Unlock Full NCT04819841 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04819841 Rescue Dossier →